We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Trump administration officials announced yesterday that 300 million doses of a COVID-19 vaccine should be available by January 2021 under Operation Warp Speed although they stressed there’s no guarantee that a vaccine will be available by then. Read More
The University of Oxford’s RECOVERY trial has found that a cheap and widely available steroid provides a benefit in COVID-19 patients and should become standard of care in patients sick enough to require oxygen. Read More
In a move to lessen India’s dependence on imports, the government is offering incentives to increase domestic manufacturing for certain drug starting materials, intermediates and active pharmaceutical ingredients (APIs). Read More
Eli Lilly has begun enrolling patients for a phase 3 trial of its rheumatoid arthritis treatment Olumiant (baricitinib) for hospitalized COVID-19 patients. Read More
Gilead Sciences has signed four more non-exclusive licensing agreements with generic drugmakers to make remdesivir available to COVID-19 patients in low-income countries. Read More
Hydroxychloroquine and chloroquine were dealt another blow as treatments for COVID-19 yesterday when the FDA revoked its Emergency Use Authorization (EUA) for the drugs — and warned that combining the antimalarials with Gilead Sciences’ remdesivir can decrease the antiviral activity of remdesivir. Read More
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance to provide up to 400 million doses of its COVID-19 vaccine at no profit starting by the end of the year. Read More